Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer

Authors: Pearson, Andrew DJ, DuBois, Steven G., Macy, Margaret E., de Rojas, Teresa, Donoghue, Martha, Weiner, Susan, Knoderer, Holly, Bernardi, Ronald, Buenger, Vickie, Canaud, Guillaume, Cantley, Lewis, Chung, John, Fox, Elizabeth, Friend, John, Glade-Bender, Julia, Gorbatchevsky, Igor, Gore, Lia, Gupta, Abha, Hawkins, Douglas S., Juric, Dejan, Lang, Leigh Anna, Leach, Danielle, Liaw, Danny, Lesa, Giovanni, Ligas, Franca, Lindberg, Gavin, Lindberg, Wendy, Ludwinski, Donna, Marshall, Lynley, Mazar, Andrew, McDonough, Joe, Nysom, Karsten, Ours, Christopher, Pappo, Alberto, Parsons, D.William, Rosenfeld, Amy, Scobie, Nicole, Smith, Malcolm, Taylor, Danielle, Weigel, Brenda, Weinstein, Amy, Karres, Dominik, Vassal, Gilles

Source: In European Journal of Cancer August 2024 207

Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study

Authors: Layman, Rachel M ^*, Han, Hyo S, Rugo, Hope S, Stringer-Reasor, Erica M, Specht, Jennifer M, Dees, E Claire, Kabos, Peter, Suzuki, Samuel, Mutka, Sarah C, Sullivan, Brian F, Gorbatchevsky, Igor, Wesolowski, Robert

Source: In The Lancet Oncology April 2024 25(4):474-487

Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Authors: Lenz, Georg, Hawkes, Eliza, Verhoef, Gregor, Haioun, Corinne, Thye Lim, Soon, Seog Heo, Dae, Ardeshna, Kirit, Chong, Geoffrey, Haaber, Jacob, Shi, Wei, Gorbatchevsky, Igor, Lippert, Susanne, Hiemeyer, Florian, Piraino, Paolo, Beckmann, Georg, Peña, Carol, Buvaylo, Viktoriya, Childs, Barrett H., Salles, Gilles

Source: Leukemia; February 2024, Vol. 38 Issue: 2 p469-472, 4p

Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial

Authors: Pettengell, Ruth, Coiffier, Bertrand, Narayanan, Geetha, de Mendoza, Fernando Hurtado, Digumarti, Raghunadharao, Gomez, Henry, Zinzani, Pier Luigi, Schiller, Gary, Rizzieri, David, Boland, Giles, Cernohous, Paul, Wang, Lixia, Kuepfer, Christine, Gorbatchevsky, Igor, Singer, Jack W

Source: In Lancet Oncology July 2012 13(7):696-706

Coastal: A phase 3 study of the PI3Kδ inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL).

Authors: Jurczak, Wojciech, Zinzani, Pier Luigi, Cunningham, David, Yavrom, Sharon, Huang, Wenying, Gorbatchevsky, Igor, Ribrag, Vincent

Source: Journal of clinical oncology. 39(15 suppl):TPS7573-TPS7573

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173216096.0x000001&indx=1&recIds=ETOCvdc_100173216096.0x000001

Efficacy and safety of the PI3Kδ inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24).

Authors: Pagel, John M., Reddy, Nishitha, Jagadeesh, Deepa, Stathis, Anastasios, Asch, Adam Steven, Salman, Huda S., Kenkre, Vaishalee Padgaonkar, Soumerai, Jacob Drobnyk, Llorin-Sangalang, Judith, Gorbatchevsky, Igor, Li, Joanne, Zelenetz, Andrew David

Source: Journal of clinical oncology. 39(15 suppl):7550-7550

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173215977.0x000001&indx=1&recIds=ETOCvdc_100173215977.0x000001

Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies.

Authors: Soumerai, Jacob Drobnyk, Jagadeesh, Deepa, Salman, Huda S., Lossos, Izidore S., Asch, Adam Steven, Reddy, Nishitha, Kenkre, Vaishalee Padgaonkar, Pagel, John M., Persky, Daniel O, Awan, Farrukh Tauseef, Magid Diefenbach, Catherine S., Huang, Wenying, Llorin-Sangalang, Judith, Gorbatchevsky, Igor, Zelenetz, Andrew David

Source: Journal of clinical oncology. 39(15 suppl):7553-7553

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173215959.0x000001&indx=1&recIds=ETOCvdc_100173215959.0x000001

EXTEND PIX301: A Phase III Randomized Trial of Pixantrone Versus Other Chemotherapeutic Agents as Third-Line Monotherapy in Patients with Relapsed, Aggressive Non-Hodgkin's Lymphoma

Authors: Engert, Andreas, Herbrecht, Rauol, Santoro, Armando, Zinzani, Pier Luigi, Gorbatchevsky, Igor

Source: In Clinical Lymphoma & Myeloma September 2006 7(2):152-154

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Authors: Lenz, Georg, Hawkes, Eliza, Verhoef, Gregor, Haioun, Corinne, Thye Lim, Soon, Seog Heo, Dae, Ardeshna, Kirit, Chong, Geoffrey, Haaber, Jacob, Shi, Wei, Gorbatchevsky, Igor, Lippert, Susanne, Hiemeyer, Florian, Piraino, Paolo, Beckmann, Georg, Peña, Carol, Buvaylo, Viktoriya, Childs, Barrett H., Salles, Gilles

Source: Leukemia; August 2020, Vol. 34 Issue: 8 p2184-2197, 14p

This result is not displayed to guests.
Login for full access.

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Authors: Zelenetz, Andrew D., Zinzani, Pier Luigi Luigi, Chan, Henry ^*, Buske, Christian, Ribrag, Vincent, Cunningham, David ^*, Jurczak, Wojciech, Abrisqueta, Pau ^*, Li, Joanne ^*, Gorbatchevsky, Igor, Brown, Jennifer R.

Source: In Blood 13 November 2019 134 Supplement 1:5244-5244

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).

Authors: Hurvitz, Sara A., Andre, Fabrice, Cristofanilli, Massimo, Curigliano, Giuseppe, Giordano, Antonio, Han, Hyo S., Martin, Miguel, Pistilli, Barbara, Rugo, Hope S., Wesolowski, Robert, Suzuki, Samuel, Mutka, Sarah, Gorbatchevsky, Igor, Loibl, Sibylle

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS1118-TPS1118, 1p

Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma

Authors: Cunningham, David ^*, Zinzani, Pier Luigi, Assouline, Sarit E., Bouabdallah, Krimo ^*, Bron, Dominique, Haioun, Corinne, Mollica, Luigina, Giurescu, Marius ^*, Gorbatchevsky, Igor, Neves, Manoel ^*, Lemos, Marta M., Grunert, Julia ^*, Hiemeyer, Florian ^*, Childs, Barrett H., Dreyling, Martin H.

Source: In Blood 3 December 2015 126(23):3935-3935

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.